The role of endogenous opioids in enhancing the antinociception produced by the combination of Δ9-tetrahydrocannabinol and morphine in the spinal cord

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 608-616

  Pugh Jr , George ^a   Smith, Peter B ^a   Dombrowski, Daniel S ^a   Welch, Sandra P ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BESTATIN; CAPTOPRIL; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DIMETHYL SULFOXIDE; DRONABINOL; DYNORPHIN A; DYNORPHIN[1-13]; DYNORPHIN[1-8]; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LEUCINE ENKEPHALIN; MORPHINE; MU OPIATE RECEPTOR; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HYPOTHERMIA; INTRATHECAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESIA; ANALGESICS; ANIMALS; BODY TEMPERATURE; CALCIUM; CATALEPSY; DRUG SYNERGISM; DYNORPHINS; MALE; MICE; MORPHINE; RABBITS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; SPINAL CORD; TETRAHYDROCANNABINOL;

EID: 12644287543     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. 8. J. Neurochem. 48: 284-292, 1987.
2. AKIL, H., MADDEN, J., PATRICK, R. L. AND BARCHAS, J. D.: Stress-induced increase in endogenous opioid peptides: Concurrent analgesia and its partial reversal by naloxone. In Opiates and Endogenous Opioid Peptides, ed. by H. Kosterlitz, pp. 63-70, Elsevier, New York, 1976.
3. CARDENAS, H. L. AND ROSS, D. H.: Calcium depletion of synaptosomes after morphine treatment. Br. J. Pharmacol. 57: 521-526, 1976.
4. CHEN, Y., MESTEK, A., LIU, J., HURLEY, J. A. AND YU, L.: Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44: 8-12, 1993.
5. CHU, T. G. AND ORLOWSKI, M..: Active-site directed N-carboxy-methyl peptide inhibitors of a soluble metallopeptidase from rat brain. Biochemistry 23: 3598-3603, 1984.
6. CHU, T. G. AND ORLOWSKI, M.: Soluble metalloendopeptidase from rat brain: Action on enkephalin-containing peptides and other bioactive peptides. Endocrinology 116: 1418-1425, 1985.
7. D'AMOUR, F. E. AND SMITH, D. L.: A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72: 74-79, 1941.
8. DEVANE, W. A., HANUS, L., BREUER, A., PERTWEE, R. G., STEVENSON, L. A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. AND MECHOULAM, R.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash. DC) 268: 1946-1949, 1992.
9. DEWEY, W. L.: Cannabinoid pharmacology. Pharmacol. Rev. 38: 151-78, 1986.
10. 5]enkephalin from dynorphin A(1-8) by rat central nervous tissue in vitro. J. Neurochem. 54: 1379-1385, 1990.
11. DUNNETT, C. W.: A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50: 1096-1121, 1955.
12. FUJIMOTO, J. M., ARTS, K. S., RADY, J. J. AND TSENG, L. F.: Spinal Dynorphin A (1-17): Possible mediator of antianalgesic action. Neuropharmacology 29: 609-617, 1990.
13. HARRIS, L. S. AND PIERSON, A. K.: Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 143: 141-148, 1983.
14. HARRIS, R. A. AND STOKES, J. A.: Cannabinoids inhibit calcium uptake by brain synaptosomes. J. Neurosci. 2: 443-447, 1982.
15. HORAN, P., TALLARIDA, R. J., HAASETH, R. C., MATSUNAGA, T. O., HRUBY, V. J. AND PORRECA, F.: Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: Supra- and sub-additivity. Life Sci. 50: 1535-1541, 1992.
16. HYLDEN, J. L. K. AND WILCOX, G. L.: Pharmacological characterization of substanceP-induced nociception in mice: Modulation by opioid and noradrenergic agonists at the spinal level. Eur. J. Pharmacol. 67: 313-404, 1983.
17. JHAMANDAS, K. AND SUTAK, M.: Comparative spinal analgesic action of dynorphin 1-8, dynorphin 1-13, and a κ-receptor agonist U50,488. Can. J. Physiol. Pharmacol. 64: 263-268, 1986.
18. LITCHFIELD, S. T. AND WILCOXON, F.: A simplified method of evaluating dose effect experiments. J. Pharmacol. Exp. Ther. 96: 99-113, 1949.
19. KEST, B., ORLOWSKI, M. AND BODNAR, R.: Endopeptidase 24.15 inhibition and opioid antinociception. Psychopharmacology 106: 408-416, 1992.
20. KIEFFER, B. L., BEFORT, K., GAVERIAUX-RUFF, C. AND HIRTH, C. G.: The ∂-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Neurobiology 89: 12048-12052, 1992.
21. MATSUDA, L. A., LOLAIT, S. J., BROWNSTEIN, M. J., YOUNG, A. C. AND BONNER, T. I: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond.) 346: 561-564, 1990.
22. MAYER, D. J., WOLFE, T. L., AKIL, H., CARDER, B. AND LIEBESKIND, J. C.: Analgesia from electrical stimulation in the brain stem of the rat. Science (Wash. DC) 174: 1351-54, 1971.
23. MCKNIGHT, A. T., CORBETT, A. D. AND KOSTERLITZ, H. W.: Increase in the potency of opioid peptides after peptidase inhibition. Eur. J. Pharmacol. 86: 393-402, 1983.
24. MIASKOWSKI, C., YETUNDE, O. T. AND LEVINE, J. D.: κ- And ∂-opioid agonists synergize to produce potent analgesia. Brain Res. 509: 165-168, 1990.
25. MOLINEAUX, C. J. AND AYALA, J. M.: An inhibitor of endopeptidase-24.15 blocks the degradation of intraventricularly administered dynorphins. J. Neurochem. 55: 611-618, 1990.
26. MUNRO, S., THOMAS, K. L. AND ABU-SHAAR.: Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond.) 365: 61-64, 1993.
27. PERTWEE, R. G.: The ring test: A quantitative method for assessing the "cataleptic" effects of cannabis in mice. Br. J. Pharmacol. 46: 753-763, 1972.
28. PORRECA, F., TAKEMORI, A. E., SULTANA, M., PORTOGHESE, P. S., BOWEN, W. D. AND MOSBERG, H. I.: Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J. Pharmacol. Exp. Ther. 263: 147-152, 1992.
29. PUGH, G., WELCH, S. P. AND BASS, P. P.: Modulation of free intracellular calcium and c-AMP by morphine and cannabinoids, alone and in combination in mouse brain and spinal cord synaptosomes. Pharmacol. Biochem. Behav. 49: 1093-1100, 1994.
30. RICHARDSON, D. E. AND AKIL, H.: Pain reduction by electrical brain stimulation in man (part 2): Chronic self-administration in the periventricular gray matter. J. Neurosurg. 47: 184-194, 1977.
31. RINALDI-CARMONA, M., BARTH, F., HEAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NELIAT, G. AND CAPUT, D.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS. Lett, 350: 240-244, 1994.
32. 3H]leucine enkephalin to a particulate fraction of rat brain. Mol. Pharmacol. 21: 538-547, 1982.
33. 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268: 1382-1387, 1994.
34. SUTTERS, K. A., MIASKOWSKI, C., TAIWO, Y. O. AND LEVINE, J. D.: Analgesic synergy and improved motor function produced by combinations of μ-∂ and μ-κ opioids. Brain Res. 530: 290-294, 1990.
35. TAKEMORI, A. E., HO, B. Y., NAESETH, J. S. AND PORTOGHESE, P. S.: Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246: 255-258, 1988.
36. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs, pp. 19-26. Springer-Verlag, New York, 1987.
37. VAUGHT, J. L., ROTHMAN, R. B. AND WESTFALL, T. C.: Mu and delta receptors: Their role in analgesia and in the differential effects of opioid peptides on analgesia. Life Sci. 30: 1443-55, 1982.
38. VAUGHT, J. L. AND TAKEMORI, A. E.: Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J. Pharmacol. Exp. Ther. 208: 86-90, 1979.
39. WELCH, S. P.: Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI, 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265: 633-640, 1993.
40. WELCH, S. P. AND STEVENS, D. L.: Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther. 262: 10-18, 1992.
41. WERZ, M. A., GREGA, D. S. AND MACDONALD, R. L.: Actions of mu, delta, and kappa opioid agonists and antagonists on mouse primary afferent neurons in culture. J. Pharmacol. Exp. Ther. 224: 258-263, 1987.
42. WILSON, R. S. AND MAY, E. L.: Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J. Med. Chem. 18: 700-703, 1975.
43. YAMAMOTO, H., HARRIS, R. A., LOH, H. H. AND WAY, E. L.: Effects of acute and chronic morphine treatments on calcium localization and binding in brain. J. Pharmacol. Exp. Ther. 205: 255-264, 1978.
44. YASUDA, K., RAYNOR, K., HAEYOUNG, K., BREDEH, C. D., TAKEDA, J., REISINE, T. AND BELL, G. I.: Cloning and functional comparison of κ and ∂ opioid receptors from mouse brain. Neurobiology 90: 6736-6740, 1993.